CCL17 and Alzheimer disease: For example, participants with chronic kidney disease reported changes in IL-1α, IL-6, and MMPs-9 and −12 (106), while we observed changes in IL-6, TARC/CCL17, IL-17A, I-TAC/CXCL11, Eotaxin-2/CCL24, Eotaxin/CCL11, and MIP-1a in our AD study participants (99).